ITGB5 is a transmembrane glycoprotein that pairs with the αV subunit to form the αVβ5 integrin heterodimer. This complex binds ligands like vitronectin and fibronectin via the RGD motif, mediating cell-matrix interactions . The FITC-conjugated ITGB5 antibody enables fluorescent detection of this protein in live or fixed samples.
ITGB5 FITC-conjugated antibodies are validated for diverse techniques:
Specificity: Confirmed via knockdown/overexpression studies .
Cross-Reactivity: Human and mouse ; predicted reactivity with rat .
Citations: Peer-reviewed studies (e.g., 29 publications for ab15459) .
TSCC: High ITGB5 expression correlates with lymph node metastasis and poor prognosis. ROS-induced ITGB5 upregulation promotes EMT and metastasis via cell adhesion pathways .
Breast Cancer: ITGB5 drives migration, proliferation, and tumor angiogenesis through Src-FAK and MEK-ERK signaling .
Cell Adhesion: Mediates binding to vitronectin and fibronectin .
Signaling: Activates FAK (Tyr861), Paxillin (Tyr31), and ERK1/2 pathways .
Cross-Reactivity: Potential off-target binding in murine models .
Sample Compatibility: Performance varies by cell type (e.g., ineffective in lymphoblastoid cells) .
Storage Stability: FITC fluorescence degrades with light exposure; requires dark storage .